These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 23837154

  • 21. Efinaconazole 10% solution in the treatment of onychomycosis of the toenails.
    Joseph WS, Vlahovic TC, Pillai R, Olin JT.
    J Am Podiatr Med Assoc; 2014; 104(5):479-85. PubMed ID: 25275736
    [Abstract] [Full Text] [Related]

  • 22. Is Severity of Disease a Prognostic Factor for Cure Following Treatment of Onychomycosis?
    Elewski BE, Cantrell W, Lin T.
    J Drugs Dermatol; 2018 Feb 01; 17(2):175-178. PubMed ID: 29462225
    [Abstract] [Full Text] [Related]

  • 23. Ciclopirox nail lacquer for the treatment of onychomycosis: an open non-comparative study.
    Shemer A, Nathansohn N, Trau H, Amichai B, Grunwald MH.
    J Dermatol; 2010 Feb 01; 37(2):137-9. PubMed ID: 20175847
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Total Dystrophic Onychomycosis Successfully Treated with Efinaconazole Topical Solution in Times of Coronavirus Disease of 2019: A Case Study.
    Garoufalis MG.
    J Am Podiatr Med Assoc; 2022 Apr 27; 112(2):. PubMed ID: 34698843
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Efinaconazole (Jublia) for the treatment of onychomycosis.
    Gupta AK, Simpson FC.
    Expert Rev Anti Infect Ther; 2014 Jul 27; 12(7):743-52. PubMed ID: 24850511
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Efinaconazole: a new topical treatment for onychomycosis.
    Gupta AK, Simpson FC.
    Skin Therapy Lett; 2014 Jul 27; 19(1):1-4. PubMed ID: 24570290
    [Abstract] [Full Text] [Related]

  • 30. Onychomycosis: rationalization of topical treatment.
    Shemer A, Trau H, Davidovici B, Amichai B, Grunwald MH.
    Isr Med Assoc J; 2008 Jun 27; 10(6):415-6. PubMed ID: 18669135
    [Abstract] [Full Text] [Related]

  • 31. Ungual hyalohyphomycosis caused by Fusarium proliferatum in an immunocompetent patient.
    Noguchi H, Hiruma M, Matsumoto T, Kano R, Ihn H.
    J Dermatol; 2017 Jan 27; 44(1):88-90. PubMed ID: 27607919
    [Abstract] [Full Text] [Related]

  • 32. Efinaconazole and Tavaborole.
    Poulakos M, Grace Y, Machin JD, Dorval E.
    J Pharm Pract; 2017 Apr 27; 30(2):245-255. PubMed ID: 26873506
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Topical therapy for toenail onychomycosis: an evidence-based review.
    Gupta AK, Daigle D, Foley KA.
    Am J Clin Dermatol; 2014 Dec 27; 15(6):489-502. PubMed ID: 25257931
    [Abstract] [Full Text] [Related]

  • 35. Update on Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis.
    Gupta AK, Studholme C.
    Skin Therapy Lett; 2016 Nov 27; 21(6):7-11. PubMed ID: 27825175
    [Abstract] [Full Text] [Related]

  • 36. Topical efinaconazole: A promising therapeutic medication for tinea unguium.
    Noguchi H, Matsumoto T, Hiruma M, Asao K, Hirose M, Fukushima S, Ihn H.
    J Dermatol; 2018 Oct 27; 45(10):1225-1228. PubMed ID: 30035311
    [Abstract] [Full Text] [Related]

  • 37. The low keratin affinity of efinaconazole contributes to its nail penetration and fungicidal activity in topical onychomycosis treatment.
    Sugiura K, Sugimoto N, Hosaka S, Katafuchi-Nagashima M, Arakawa Y, Tatsumi Y, Jo Siu W, Pillai R.
    Antimicrob Agents Chemother; 2014 Jul 27; 58(7):3837-42. PubMed ID: 24752277
    [Abstract] [Full Text] [Related]

  • 38. The Presence of an Air Gap Between the Nail Plate and Nail Bed in Onychomycosis Patients: Treatment Implications for Topical Therapy.
    Gupta AK, Pillai R.
    J Drugs Dermatol; 2015 Aug 27; 14(8):859-63. PubMed ID: 26267730
    [Abstract] [Full Text] [Related]

  • 39. Efficacy of long-term treatment with efinaconazole 10% solution in patients with onychomycosis, including severe cases: A multicenter, single-arm study.
    Iozumi K, Abe M, Ito Y, Uesugi T, Onoduka T, Kato I, Kato F, Kodama K, Takahashi H, Takeda O, Tomizawa K, Nomiyama T, Fujii M, Mayama J, Muramoto F, Yasuda H, Yamanaka K, Sato T, Oh-I T, Kasai H, Tsuboi R, Hattori N, Maruyama R, Omi T, Shimoyama H, Sei Y, Nakasu I, Nishimoto S, Hata Y, Mochizuki T, Fukuzawa M, Seishima M, Sugiura K, Katayama I, Yamamoto O, Shindo M, Kiryu H, Kusuhara M, Takenaka M, Watanabe S.
    J Dermatol; 2019 Aug 27; 46(8):641-651. PubMed ID: 31206779
    [Abstract] [Full Text] [Related]

  • 40. Preparation and in vivo evaluation of a highly skin- and nail-permeable efinaconazole topical formulation for enhanced treatment of onychomycosis.
    Lee BC, Pangeni R, Na J, Koo KT, Park JW.
    Drug Deliv; 2019 Dec 27; 26(1):1167-1177. PubMed ID: 31738083
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.